CMV gB vaccine

BIOLOGICAL3 trials

Sponsors

Robert Pass, MD, National Institute of Allergy and Infectious Diseases (NIAID), University College, London

Conditions

Cytomegalovirus Infections

Phase 2

Recombinant CMV gB Vaccine in Postpartum Women

CompletedNCT00125502

Robert Pass, MDCytomegalovirus Infections

Start: 1999-08-31End: 2010-01-31Updated: 2011-09-20

gB/MF59 Vaccine in Preventing Cytomegalovirus Infection in Healthy Adolescent Females

CompletedNCT00133497

National Institute of Allergy and Infectious Diseases (NIAID)Cytomegalovirus Infections

Start: 2006-06-30End: 2013-06-30Updated: 2017-07-06

CMV Glycoprotein B Vaccine in Allograft Recipients

University College, LondonCytomegalovirus Infections

Start: 2006-08-31End: 2011-09-30Updated: 2010-04-19

Related Papers

Human Cytomegalovirus mRNA-1647 Vaccine Candidate Elicits Potent and Broad Neutralization and Higher Antibody-Dependent Cellular Cytotoxicity Responses Than the gB/MF59 Vaccine.

2024-08-0148 citations

The cytomegalovirus gB/MF59 vaccine candidate induces antibodies against an antigenic domain controlling cell-to-cell spread

Nature Communications2023-02-2329 citations

Cytomegalovirus glycoprotein-B vaccine with MF59 adjuvant in transplant recipients: a phase 2 randomised placebo-controlled trial.

2011-04-01311 citations

Vaccine prevention of maternal cytomegalovirus infection.

2009-03-01522 citations